SignalXSignalX

NGVT Ingevity Corp

Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Chemicals & Allied ProductsSEC EDGAR
Ingevity Corp Overview

Ingevity Corp (NGVT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • Newly added trade policy risk from new U.S. tariffs and Chinese retaliatory measures lowering margins on products sold into China
  • • Materially updated operational risk of facility disruptions, including labor strikes with recent CBA expirations and renewals through mid-2025
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$263M

Net Income

$44M

Gross Margin

46.5%

Net Margin

16.5%

ROE

31.5%

Total Assets

$1.8B

Source: XBRL data from Ingevity Corp Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Ingevity Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.